Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

被引：4

作者：

Buyukasik, Yahya ^{[1
]}

机构：

[1] Hacettepe Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey

来源：

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI | 2011年 / 21卷 / 02期

关键词：

Chronic myeloid leukemia; Targeted therapy; Imatinib; Dasatinib; Nilotinib; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL MUTATIONS; CHRONIC-PHASE; FOLLOW-UP; CYTOGENETIC RESPONSES; EUROPEAN LEUKEMIANET; SUBOPTIMAL RESPONSE; DASATINIB; RESISTANT; NILOTINIB;

D O I：

10.4999/uhod.11012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.

引用

页码：4 / 9

页数：6

共 23 条

[11] Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL [J].

Kantarjian, Hagop ;

Giles, Francis ;

Wunderle, Lydia ;

Bhalla, Kapil ;

O'Brien, Susan ;

Wassmann, Barbara ;

Tanaka, Chiaki ;

Manley, Paul ;

Rae, Patricia ;

Mietlowski, William ;

Bochinski, Kathy ;

Hochhaus, Andreas ;

Griffin, James D. ;

Hoelzer, Dieter ;

Albitar, Maher ;

Dugan, Margaret ;

Cortes, Jorge ;

Alland, Leila ;

Ottmann, Oliver G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2542-2551

[12] Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily Two-Year Follow-Up of a Randomized Phase 2 Study (START-R) [J].

Kantarjian, Hagop ;

Pasquini, Ricardo ;

Levy, Vincent ;

Jootar, Saengsuree ;

Holowiecki, Jerzy ;

Hamerschlak, Nelson ;

Hughes, Timothy ;

Bleickardt, Eric ;

Dejardin, David ;

Cortes, Jorge ;

Shah, Neil P. .

CANCER, 2009, 115 (18) :4136-4147

[13] Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up [J].

Kantarjian, Hagop ;

Cortes, Jorge ;

Kim, Dong-Wook ;

Dorlhiac-Llacer, Pedro ;

Pasquini, Ricardo ;

DiPersio, John ;

Mueller, Martin C. ;

Radich, Jerald P. ;

Khoury, H. Jean ;

Khoroshko, Nina ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Tallman, Martin S. .

BLOOD, 2009, 113 (25) :6322-6329

[14] Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance [J].

Kantarjian, Hagop M. ;

Giles, Francis ;

Gattermann, Norbert ;

Bhalla, Kapil ;

Alimena, Giuliana ;

Palandri, Francesca ;

Ossenkoppele, Gert J. ;

Nicolini, Franck-Emmanuel ;

O'Brien, Stephen G. ;

Litzow, Mark ;

Bhatia, Ravi ;

Cervantes, Francisco ;

Haque, Ariful ;

Shou, Yaping ;

Resta, Debra J. ;

Weitzman, Aaron ;

Hochhaus, Andreas ;

le Coutre, Philipp .

BLOOD, 2007, 110 (10) :3540-3546

[15]

Lahaye T, 2005, CANCER, V103, P659

[16] European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor [J].

Marin, David ;

Milojkovic, Dragana ;

Olavarria, Eduardo ;

Khorashad, Jamshid S. ;

de lavallade, Hugues ;

Reid, Alistair G. ;

Foroni, Letizia ;

Rezvani, Katayoun ;

Bua, Marco ;

Dazzi, Francesco ;

Pavlu, Jiri ;

Klammer, Matthias ;

Kaeda, Jaspal S. ;

Goldman, John M. ;

Apperley, Jane F. .

BLOOD, 2008, 112 (12) :4437-4444

[17] Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations [J].

Mueller, Martin C. ;

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Druker, Brian J. ;

Erben, Philipp ;

Pasquini, Ricardo ;

Branford, Susan ;

Hughes, Timothy P. ;

Radich, Jerald P. ;

Ploughman, Lynn ;

Mukhopadhyay, Jaydip ;

Hochhaus, Andreas .

BLOOD, 2009, 114 (24) :4944-4953

[18]

SAGLIO G, 2008, 50 AM SOC HEM ANN M, P3226

[19] Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV [J].

Saussele, Susanne ;

Lauseker, Michael ;

Gratwohl, Alois ;

Beelen, Dietrich W. ;

Bunjes, Donald ;

Schwerdtfeger, Rainer ;

Kolb, Hans-Jochem ;

Ho, Anthony D. ;

Falge, Christiane ;

Holler, Ernst ;

Schlimok, Guenter ;

Zander, Axel R. ;

Arnold, Renate ;

Kanz, Lothar ;

Dengler, Robert ;

Haferlach, Claudia ;

Schlegelberger, Brigitte ;

Pfirrmann, Markus ;

Mueller, Martin C. ;

Schnittger, Susanne ;

Leitner, Armin ;

Pletsch, Nadine ;

Hochhaus, Andreas ;

Hasford, Joerg ;

Hehlmann, Ruediger .

BLOOD, 2010, 115 (10) :1880-1885

[20] Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia [J].

Shah, Neil P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Rea, Delphine ;

Dorlhiac-Llacer, Pedro E. ;

Milone, Jorge H. ;

Vela-Ojeda, Jorge ;

Silver, Richard T. ;

Khoury, H. Jean ;

Charbonnier, Aude ;

Khoroshko, Nina ;

Paquette, Ronald L. ;

Deininger, Michael ;

Collins, Robert H. ;

Otero, Irma ;

Hughes, Timothy ;

Bleickardt, Eric ;

Strauss, Lewis ;

Francis, Stephen ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) :3204-3212

← 1 2 3 →